TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ) is now available.
Resmed Inc has filed a Form 144 with the SEC, indicating a proposed sale of 50 shares of common stock by Officer Michael J. Rider. The shares, acquired through restricted stock vesting, are set to be sold on December 1, 2025, on the NYSE with an aggregate market value of $12,208. This filing is part of a planned transaction under Rule 10b5-1, ensuring compliance with insider trading regulations. The sale is not expected to impact the company’s operations or market position significantly, as it represents a small fraction of the total shares outstanding.
The most recent analyst rating on (AU:RMD) stock is a Buy with a A$45.00 price target. To see the full list of analyst forecasts on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh stock, see the AU:RMD Stock Forecast page.
More about Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
Resmed Inc is a company operating in the healthcare industry, specializing in the development and manufacturing of equipment related to sleep disorders and respiratory care. The company focuses on providing innovative solutions for patients with sleep apnea and chronic obstructive pulmonary disease (COPD), aiming to improve their quality of life through advanced technology.
Average Trading Volume: 1,234,875
Technical Sentiment Signal: Buy
Current Market Cap: A$56.99B
Find detailed analytics on RMD stock on TipRanks’ Stock Analysis page.